Laura Prendergast
Stock Analyst at Stifel Nicolaus
(4.64)
# 830
Out of 4,408 analysts
76
Total ratings
54.4%
Success rate
33.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Laura Prendergast
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COGT Cogent Biosciences | Maintained: Buy | $45 | $33.06 | +36.14% | 9 | Jun 15, 2026 | |
| ORIC ORIC Pharmaceuticals | Initiated Coverage: Buy | $14 | $8.36 | +67.56% | 1 | Jun 12, 2026 | |
| NUVL Nuvalent | Downgraded: Hold | $135 → $124 | $123.35 | +0.53% | 7 | Jun 10, 2026 | |
| RVMD Revolution Medicines | Maintained: Buy | $215 | $160.06 | +34.32% | 17 | Jun 1, 2026 | |
| FHTX Foghorn Therapeutics | Maintained: Buy | $12 | $4.10 | +192.68% | 6 | Jun 1, 2026 | |
| ERAS Erasca | Maintained: Buy | $30 | $14.43 | +107.90% | 11 | Jun 1, 2026 | |
| TNGX Tango Therapeutics | Maintained: Buy | $40 | $32.90 | +21.58% | 9 | May 25, 2026 | |
| BDTX Black Diamond Therapeutics | Maintained: Buy | $8 | $1.73 | +363.77% | 6 | May 22, 2026 | |
| BBOT BridgeBio Oncology Therapeutics | Maintained: Buy | $23 | $7.73 | +197.54% | 4 | May 13, 2026 | |
| OLMA Olema Pharmaceuticals | Initiated Coverage: Buy | $48 | $9.83 | +388.55% | 1 | Feb 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $15.07 | -20.37% | 3 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $4 | $8.43 | n/a | 1 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $16 | $2.74 | n/a | 1 | Aug 14, 2024 |
Cogent Biosciences
Jun 15, 2026
Maintained: Buy
Price Target: $45
Current: $33.06
Upside: +36.14%
ORIC Pharmaceuticals
Jun 12, 2026
Initiated Coverage: Buy
Price Target: $14
Current: $8.36
Upside: +67.56%
Nuvalent
Jun 10, 2026
Downgraded: Hold
Price Target: $135 → $124
Current: $123.35
Upside: +0.53%
Revolution Medicines
Jun 1, 2026
Maintained: Buy
Price Target: $215
Current: $160.06
Upside: +34.32%
Foghorn Therapeutics
Jun 1, 2026
Maintained: Buy
Price Target: $12
Current: $4.10
Upside: +192.68%
Erasca
Jun 1, 2026
Maintained: Buy
Price Target: $30
Current: $14.43
Upside: +107.90%
Tango Therapeutics
May 25, 2026
Maintained: Buy
Price Target: $40
Current: $32.90
Upside: +21.58%
Black Diamond Therapeutics
May 22, 2026
Maintained: Buy
Price Target: $8
Current: $1.73
Upside: +363.77%
BridgeBio Oncology Therapeutics
May 13, 2026
Maintained: Buy
Price Target: $23
Current: $7.73
Upside: +197.54%
Olema Pharmaceuticals
Feb 11, 2026
Initiated Coverage: Buy
Price Target: $48
Current: $9.83
Upside: +388.55%
Jul 29, 2025
Maintained: Buy
Price Target: $12
Current: $15.07
Upside: -20.37%
Feb 13, 2025
Maintained: Buy
Price Target: $4
Current: $8.43
Upside: n/a
Aug 14, 2024
Upgraded: Buy
Price Target: $16
Current: $2.74
Upside: n/a